Orly Vardeny

Dec 11, 2024 | ajmc.com | Orly Vardeny

OpinionVideoDecember 11, 2024Author(s):A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.

Nov 18, 2024 | healio.com | Regina Schaffer |Richard Smith |Ankeet S. Bhatt |Orly Vardeny

Read more You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Electronic nudges promoting influenza vaccination improved vaccine uptake for older and younger adults in Denmark.

Nov 17, 2024 | jamanetwork.com | Orly Vardeny |Outcomes Research |Brian Claggett |Michele Senni

Key PointsQuestion  What is the treatment effect of finerenone, relative to placebo, in patients with heart failure with mildly reduced or preserved ejection fraction based on postrandomization potassium levels? Findings  Among 6001 patients in a clinical trial, finerenone increased potassium levels greater than 5.5 mmol/L and decreased potassium levels less than 3.5 mmol/L.

Sep 1, 2024 | jacc.org | Andrew P. Ambrosy |Orly Vardeny |Robert J. Mentz |Joycie Chang

AbstractThe pathophysiology of heart failure (HF) is related to the overactivation of the mineralocorticoid receptor (MR), leading to fluid retention and adverse myocardial remodeling.

Jan 24, 2024 | jamanetwork.com | Orly Vardeny |Outcomes Research |Akshay S. Desai |Pardeep S. Jhund

Key PointsQuestion  What is the mode of death and the association of dapagliflozin with cause-specific death in patients with heart failure with improved ejection fraction (HFimpEF)? Findings  In this post hoc analysis of the DELIVER trial including 6263 participants, 1151 participants had HFimpEF.